Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors.
about
Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelinThe development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapyAberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cellsEffect of antigen shedding on targeted delivery of immunotoxins in solid tumors from a mathematical modelA flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptakePaclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies.Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer.Quantitating antibody uptake in vivo: conditional dependence on antigen expression levels.Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers.Combination treatments with the PKC inhibitor, enzastaurin, enhance the cytotoxicity of the anti-mesothelin immunotoxin, SS1P.Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding.Killing of resistant cancer cells with low Bak by a combination of an antimesothelin immunotoxin and a TRAIL Receptor 2 agonist antibody.Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging.Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.Mesothelin-targeted agents in clinical trials and in preclinical development.Combined-modality radioimmunotherapy: synergistic effect of paclitaxel and additive effect of bevacizumabTumor and organ uptake of (64)Cu-labeled MORAb-009 (amatuximab), an anti-mesothelin antibody, by PET imaging and biodistribution studiesAntigen shedding may improve efficiencies for delivery of antibody-based anticancer agents in solid tumorsRecent Advances in the Development of Antineoplastic Agents Derived from Natural ProductsCombination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines.Mesothelin-targeted immunotherapies for malignant pleural mesothelioma.Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel.Immunotoxins: the role of the toxin.Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignanciesPhase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors.Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanesTargeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins.Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737.Immune therapies for malignant mesothelioma.α-sarcin and RNase T1 based immunoconjugates: the role of intracellular trafficking in cytotoxic efficiency.Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity.Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody.Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.Translational immunotherapeutics: chemoimmunotherapy for malignant pleural mesothelioma.A mechanistic compartmental model for total antibody uptake in tumors.A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer.A new anti-mesothelin antibody targets selectively the membrane-associated form.Tumor-Shed Antigen Affects Antibody Tumor Targeting: Comparison of Two 89Zr-Labeled Antibodies Directed against Shed or Nonshed Antigens.
P2860
Q27015134-E8561C2F-AAE5-4424-8558-77B473FDCC9DQ27314606-D24DC3CB-4FC6-481F-8030-45119E398B47Q28263206-2BB4D275-9A1D-4CB6-8AEA-5CDC92137E67Q28544295-3F1C6326-5FB2-4D0C-8FC4-E44D97141D1AQ33639027-A4A28EAF-546C-4766-AC64-A67BA728826AQ33761496-4EEFB64D-4272-43D2-A9E7-1ED612311B14Q33932779-04C520EB-221E-45CF-B784-6AC14369ACBAQ34080906-A28454A8-66ED-4E60-8FAF-5A3B7A327F3FQ34400470-5C714B4B-40CE-4BA0-92B0-FB8FC9F05D0CQ34459015-BE442179-90C1-4BAB-8847-2AED1F8DE9BFQ35018336-BBE3358E-8C00-4B1F-BC19-5A5989353E8FQ35190612-F7C60CB5-CC4B-4776-93AA-D914F1F3F93DQ35223910-B6E5B874-A035-45DB-8AE5-064F284D5C3DQ35552059-A786F150-717D-4317-B2A0-E5E68FB1EFD7Q35653164-488D2AC4-3991-4CDD-B820-7396566E07ECQ35815380-D0243448-F726-4582-BE7F-164FECEE5532Q35842769-B11B1950-3CCD-4E48-8099-C1AAB0EE4626Q36122498-8E477AA0-784B-48AD-A5E0-8636153841ACQ36129683-2D665DA2-50E7-4321-9A4D-9CF1C5826690Q36273796-52A9DA50-9F36-47A2-AADC-20A8E2E5E857Q36481165-E3350DE8-50EE-4E7F-9BDF-FE91659A7B08Q37090793-27A7EECB-4B78-42F8-A0AF-0DE7F2A62B03Q37133208-26B412DC-0040-4576-A266-B38633D42675Q37139525-137DB0BC-2504-49D8-B733-60BF377FB13EQ37165245-D893EBEA-F42F-4A7E-86C3-042345D6066FQ37368203-CF32128D-D5CD-4D1D-A743-32F6C27B5AC5Q37625758-886E582A-B48A-47C6-8C11-179B182C80A5Q37705936-92769BC4-CFFE-45F0-A2A1-A68BA2FB36DFQ37725990-4FEE276C-F2C1-4CA7-A1A4-48E4E7A4CE4AQ37877741-CF68D66E-ACC4-4B3D-904A-B7BD37C2C8CFQ38212149-0D84A5A5-24B1-4D7E-99D8-9FD24C472011Q38932236-EBC05E9C-17EA-40C6-8ED1-4BDB02B83881Q41686071-F50C9AC2-0A58-494D-A271-2DD48FD651D9Q41832797-3712B897-8428-4457-9942-0A32E5DB5439Q41934574-51988A22-0261-4592-8280-FBDDA8A480C1Q42563176-B5AD8916-0898-4F96-9D67-CB12AFC4CBABQ43066289-982016A3-CF0B-4F9A-819B-F3296CDAC394Q47128416-F1E1C846-0242-4EB4-9DB6-F40BA4183701Q51082110-EE415B32-6192-45D3-BCF2-586E9A6BD8CEQ55070515-0AAA28E4-34E5-4B6E-B817-E5734DAC5960
P2860
Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Immunotoxin and Taxol synergy ...... extracellular space of tumors.
@ast
Immunotoxin and Taxol synergy ...... extracellular space of tumors.
@en
type
label
Immunotoxin and Taxol synergy ...... extracellular space of tumors.
@ast
Immunotoxin and Taxol synergy ...... extracellular space of tumors.
@en
prefLabel
Immunotoxin and Taxol synergy ...... extracellular space of tumors.
@ast
Immunotoxin and Taxol synergy ...... extracellular space of tumors.
@en
P2093
P2860
P356
P1476
Immunotoxin and Taxol synergy ...... extracellular space of tumors.
@en
P2093
Ira Pastan
Laiman Xiang
Raffit Hassan
Yujian Zhang
P2860
P304
17099-17104
P356
10.1073/PNAS.0708101104
P407
P577
2007-10-16T00:00:00Z